Journal of Dermatological Treatment (Dec 2024)
Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis)
- Luigi Gargiulo,
- Luciano Ibba,
- Angela Alfano,
- Piergiorgio Malagoli,
- Fabrizio Amoruso,
- Anna Balato,
- Francesca Barei,
- Anna G. Burroni,
- Stefano Caccavale,
- Piergiacomo Calzavara-Pinton,
- Maria Esposito,
- Maria C. Fargnoli,
- Silvia M. Ferrucci,
- Caterina Foti,
- Giampiero Girolomoni,
- Massimo Gola,
- Mario B. Guanti,
- Carlotta Gurioli,
- Manfredi Magliulo,
- Martina Maurelli,
- Pietro Morrone,
- Maria L. Musumeci,
- Maddalena Napolitano,
- Michela Ortoncelli,
- Cataldo Patruno,
- Bianca M. Piraccini,
- Elena Pezzolo,
- Simone Ribero,
- Mariateresa Rossi,
- Paola Savoia,
- Claudio Sciarrone,
- Benedetta Tirone,
- Marco Vaccino,
- Federica Veronese,
- Antonio Costanzo,
- Alessandra Narcisi
Affiliations
- Luigi Gargiulo
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
- Luciano Ibba
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
- Angela Alfano
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
- Piergiorgio Malagoli
- Department of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, Italy
- Fabrizio Amoruso
- Dermatology Unit, Azienda Ospedaliera di Cosenza, Italy
- Anna Balato
- Dermatology Unit, University of Campania L. Vanvitelli, Naples, Italy
- Francesca Barei
- Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
- Anna G. Burroni
- Department of Dermatology, Dipartimento di Scienze della Salute (DISSAL), University of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- Stefano Caccavale
- Dermatology Unit, University of Campania L. Vanvitelli, Naples, Italy
- Piergiacomo Calzavara-Pinton
- Dermatology Department, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy
- Maria Esposito
- Department of Biotechnological and Applied Clinical Sciences, University of L’ Aquila, L’ Aquila, Italy
- Maria C. Fargnoli
- Department of Biotechnological and Applied Clinical Sciences, University of L’ Aquila, L’ Aquila, Italy
- Silvia M. Ferrucci
- Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
- Caterina Foti
- Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", Bari, Italy
- Giampiero Girolomoni
- Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy
- Massimo Gola
- Allergological and Pediatric Dermatology Unit, Department of Health Sciences, University of Florence, Florence
- Mario B. Guanti
- Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy
- Carlotta Gurioli
- Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
- Manfredi Magliulo
- Allergological and Pediatric Dermatology Unit, Department of Health Sciences, University of Florence, Florence
- Martina Maurelli
- Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy
- Pietro Morrone
- Dermatology Unit, Azienda Ospedaliera di Cosenza, Italy
- Maria L. Musumeci
- Dermatology Clinic, University of Catania, Catania, Italy
- Maddalena Napolitano
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
- Michela Ortoncelli
- Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, Italy
- Cataldo Patruno
- Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy
- Bianca M. Piraccini
- Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
- Elena Pezzolo
- Department of Dermatology, San Bortolo Hospital, Vicenza, Italy
- Simone Ribero
- Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, Italy
- Mariateresa Rossi
- Dermatology Department, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy
- Paola Savoia
- Dermatology Clinic, Department of Health Science, University of Eastern Piedmont, Novara, Italy
- Claudio Sciarrone
- Department of Dermatology, Papardo Hospital, Messina, Italy
- Benedetta Tirone
- Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", Bari, Italy
- Marco Vaccino
- Dermatology Clinic, University of Catania, Catania, Italy
- Federica Veronese
- Department of Dermatology, Papardo Hospital, Messina, Italy
- Antonio Costanzo
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
- Alessandra Narcisi
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
- DOI
- https://doi.org/10.1080/09546634.2024.2411855
- Journal volume & issue
-
Vol. 35,
no. 1
Abstract
Aim: Abrocitinib is a JAK-1 inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD). We conducted a 16-week multicenter retrospective study to assess the short-term effectiveness and safety of abrocitinib in patients with moderate-to-severe AD.Our retrospective study included 85 adult patients from 14 Italian Dermatology Units affected by moderate-to-severe AD treated with abrocitinib 100/200 mg.Methods: Effectiveness of abrocitinib at weeks 4 and 16 was assessed by using the Eczema Area and Severity Index (EASI), the Investigator Global Assessment (IGA), the peak pruritus and sleep- Numerical Rating Scale (PP-NRS and S-NRS, respectively).Results: At week 16, improvement of at least 90% in EASI (EASI90) and IGA 0/1 was observed in 49.4% and 61.2% of patients, respectively. A reduction of at least 4 points in PP-NRS and S-NRS compared with baseline was achieved by 70.6% of patients for both endpoints. No significant safety reports were observed during the study period. Naïve patients had better rates of EASI 90 compared to patients who previously failed dupilumab.Conclusion: Our data confirm the effectiveness of abrocitinib in a real-world setting with better clinical responses at weeks 4 and 16, compared with Phase-III clinical trials. Longer analyses are required to further establish the safety profile of abrocitinib.
Keywords
